Clinical Registry on Treatment Reality and Sequential Treatments of Patients with Resectable or Locally Advanced/metastatic Pancreatic Cancer in Real-life Practice in Germany
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreas Cancer
- Sponsor
- iOMEDICO AG
- Enrollment
- 2325
- Locations
- 1
- Primary Endpoint
- Treatment reality in Germany
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •resectable or locally advanced/metastatic pancreatic cancer
- •18 years and older
- •Antineoplastic treatment
- •Date of consent no later than 2 weeks after start of first-line treatment
Exclusion Criteria
- •No pancreatic cancer
- •Below 18 years and older
- •No antineoplastic treatment
- •Date of consent later than 2 weeks after start of first-line treatment
Outcomes
Primary Outcomes
Treatment reality in Germany
Time Frame: over 5 years
description of treatments selected for patients per line of therapy over the course of the project